Identification of alternative mechanisms of resistance to FGFR inhibitor treatment in FGFR1-amplified large cell compared to FGFR1-amplified small cell lung cancer models

被引：1
|
作者：
Jovcheva, Eleonora [1 ]
Ogata, Souichi [1 ]
Van De Ven, Kelly [1 ]
Paulussen, Caroline [1 ]
Van de Weyer, Inez [1 ]
Wolf, Hans D. [1 ]
Ceulemans, Hugo [1 ]
McClue, Steve [2 ]
Vialard, Jorge [1 ]
Perera, Timothy [1 ]
机构：
[1] Janssen, Beerse, Belgium
[2] Janssen, High Wycombe, Bucks, England
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-LB-329
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
329
引用
收藏
页数：2
相关论文
共 50 条
  • [11] FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway
    Ji, Wenxiang
    Yu, Yongfeng
    Li, Ziming
    Wang, Guan
    Li, Fan
    Xia, Weiliang
    Lu, Shun
    ONCOTARGET, 2016, 7 (12) : 15118 - 15134
  • [12] Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report
    Sawayama, Saki
    Murakami, Ryusuke
    Aki, Megumi
    Kawaguchi, Yusuke
    Takao, Yumi
    Nonogaki, Hirofumi
    Goto, Tomoyuki
    Yamauchi, Chikako
    GYNECOLOGIC ONCOLOGY REPORTS, 2022, 41
  • [13] Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer
    Ying Yang
    Ziming Li
    Hong Yuan
    Wenxiang Ji
    Kaixuan Wang
    Tingting Lu
    Yongfeng Yu
    Qingyu Zeng
    Fan Li
    Weiliang Xia
    Shun Lu
    Oncogenesis, 8
  • [14] Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer
    Yang, Ying
    Li, Ziming
    Yuan, Hong
    Ji, Wenxiang
    Wang, Kaixuan
    Lu, Tingting
    Yu, Yongfeng
    Zeng, Qingyu
    Li, Fan
    Xia, Weiliang
    Lu, Shun
    ONCOGENESIS, 2019, 8 (9)
  • [15] PREVALENCE, MORPHOLOGY AND NATURAL HISTORY OF FGFR1-AMPLIFIED LUNG CANCER DETECTED BY FISH AND SISH
    Russell, Prudence A.
    Yu, Yong
    Young, Richard J.
    Conron, Matthew
    Wainer, Zoe
    Alam, Naveed
    Solomon, Ben
    Wright, Gavin
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S205 - S205
  • [16] FGFR1 is associated with resistance to interaction with estrogen receptor (ER) a endocrine therapy in ER+/FGFR1-amplified breast cancer
    Formisano, Luigi
    Young, Christian D.
    Bhola, Neil
    Giltnane, Jennifer M.
    Estrada, Monica V.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2015, 75
  • [17] FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial–mesenchymal transition, and metastasis in FGFR1-amplified lung cancer
    Kaixuan Wang
    Wenxiang Ji
    Yongfeng Yu
    Ziming Li
    Xiaomin Niu
    Weiliang Xia
    Shun Lu
    Oncogene, 2018, 37 : 5340 - 5354
  • [18] Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells
    Feng Chi
    Jason I. Griffiths
    Aritro Nath
    Andrea H. Bild
    Breast Cancer Research, 26
  • [19] FGFR1 associates with gene promoters and regulates transcription in ER+/FGFR1-amplified breast cancer: Implications for endocrine resistance
    Servetto, Alberto
    Kollipara, Rahul
    Formisano, Luigi
    Lee, Kyung-min
    Lin, Albert
    Sudhan, Dhivya R.
    Hanker, Ariella B.
    Chatterjee, Sumanta
    Akamatsu, Hiroaki
    Marin, Arnaldo
    Mendiratta, Saurabh
    Kittler, Ralf
    Arteaga, Carlos L.
    CANCER RESEARCH, 2020, 80 (16)
  • [20] RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade
    Bockorny, Bruno
    Rusan, Maria
    Chen, Wankun
    Liao, Rachel G.
    Li, Yvonne
    Piccioni, Federica
    Wang, Jun
    Tan, Li
    Thorner, Aaron R.
    Li, Tianxia
    Zhang, Yanxi
    Miao, Changhong
    Ovesen, Therese
    Shapiro, Geoffrey I.
    Kwiatkowski, David J.
    Gray, Nathanael S.
    Meyerson, Matthew
    Hammerman, Peter S.
    Bass, Adam J.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (07) : 1526 - 1539
12345